driving the costs of pharmaceuticals, and develop a structured vector autoregressive (SVAR) model to measure the social rate …-run prices in pharmaceuticals themselves, but with lower long-run prices in the aggregate medical sector which includes … pharmaceuticals as a component part. Further, the TRIPS Agreement and Hatch-Waxman Act to enable generic competition have both been …

Background: Rising cancer drug prices pose a challenge for patients and healthcare systems in the US. Whilst prices are … routinely assigned to a drug’s original indication receiving US Food and Drug Administration (FDA) approval, the influence of … drug prices, distinctly analyzing original and supplemental indications.Data and Methods: Clinical trial evidence …

generic entry only if all patents on a drug were public-sector patents. In this paper, we examine the feasibility of using … march-in rights to lower pharmaceutical prices by examining patents on drugs approved by the U.S. Food and Drug …

any large pharmaceutical firms based in Finland, by the 1950s a similar partnership between medical experts and drug … national project and collaboration officially encouraged. After the Second World War the drug industry was no longer local, but … the close physician-drug industry relationship largely continued as before. There are indications today that both …

We study cartels that operated in the US generic drug industry, leveraging quarterly Medicaid data from 2011-2018 and a … across- and within-drug heterogeneity. We focus on six drug markets that that were part of the expanded initial complaint and …